ACET ADICET BIO INC Product Launches 8-K Filing 2024 - Clinical Trial Update Adicet Bio, Inc. announced that the first patient has been dosed in a Phase 1 clinical trial for ADI-270, targeting metastatic/advanced clear cell renal cell carcinoma, with preliminary data expected in the first half of 2025.Get access to all SEC 8-K filings of the ADICET BIO INC